SURMOUNT-OSA
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SURMOUNT-OSA?
Tirzepatide 10/15 mg weekly in obstructive sleep apnea with obesity.
The apnea-hypopnea index improved roughly 50% against placebo, which is the kind of result that changes what a sleep clinic prescribes.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SURMOUNT-OSA comes up on this site
On GLP Watchdog, SURMOUNT-OSA comes up in 2 research articles and 1 tool.
Research that discusses it
Tools that use it
Connected terms
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers